Search

Your search keyword '"Sharpe, Rowena"' showing total 3 results
Start Over Author "Sharpe, Rowena" Journal the lancet respiratory medicine
3 results on '"Sharpe, Rowena"'

1. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Author

Williams, Bryan, Turner, Rebecca, Libri, Vincenzo, Mussai, Francis, Middleton, Gary, Bowden, Sarah, Bangash, Mansoor, Gao-Smith, Fang, Patel, Jaimin, Sapey, Elizabeth, Thomas, Mark, Coles, Mark, Watkinson, Peter, Rahman, Naj, Angus, Brian, Mentzer, Alexander J., Novak, Alex, Feldman, Marc, Richter, Alex, Faustini, Sian, Bathurst, Camilla, Van de Wiel, Joseph, Mee, Susie, James, Karen, Rahman, Bushra, Turner, Karen, Hill, Adam, Gordon, Anthony, Yap, Christina, Matthay, Michael, McAuley, Danny, Hall, Andrew, Dark, Paul, McMichael, Andrew, Fisher, Benjamin A, Veenith, Tonny, Slade, Daniel, Gaskell, Charlotte, Rowland, Matthew, Whitehouse, Tony, Scriven, James, Parekh, Dhruv, Balasubramaniam, Madhu S, Cooke, Graham, Morley, Nick, Gabriel, Zoe, Wise, Matthew P, Porter, Joanna, McShane, Helen, Ho, Ling-Pei, Newsome, Philip N, Rowe, Anna, Sharpe, Rowena, Thickett, David R, Bion, Julian, Gates, Simon, Richards, Duncan, and Kearns, Pamela

Published
2022
Full Text
View/download PDF

2. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Author

Fisher, Benjamin A, primary, Veenith, Tonny, additional, Slade, Daniel, additional, Gaskell, Charlotte, additional, Rowland, Matthew, additional, Whitehouse, Tony, additional, Scriven, James, additional, Parekh, Dhruv, additional, Balasubramaniam, Madhu S, additional, Cooke, Graham, additional, Morley, Nick, additional, Gabriel, Zoe, additional, Wise, Matthew P, additional, Porter, Joanna, additional, McShane, Helen, additional, Ho, Ling-Pei, additional, Newsome, Philip N, additional, Rowe, Anna, additional, Sharpe, Rowena, additional, Thickett, David R, additional, Bion, Julian, additional, Gates, Simon, additional, Richards, Duncan, additional, Kearns, Pamela, additional, Williams, Bryan, additional, Turner, Rebecca, additional, Libri, Vincenzo, additional, Mussai, Francis, additional, Middleton, Gary, additional, Bowden, Sarah, additional, Bangash, Mansoor, additional, Gao-Smith, Fang, additional, Patel, Jaimin, additional, Sapey, Elizabeth, additional, Thomas, Mark, additional, Coles, Mark, additional, Watkinson, Peter, additional, Rahman, Naj, additional, Angus, Brian, additional, Mentzer, Alexander J., additional, Novak, Alex, additional, Feldman, Marc, additional, Richter, Alex, additional, Faustini, Sian, additional, Bathurst, Camilla, additional, Van de Wiel, Joseph, additional, Mee, Susie, additional, James, Karen, additional, Rahman, Bushra, additional, Turner, Karen, additional, Hill, Adam, additional, Gordon, Anthony, additional, Yap, Christina, additional, Matthay, Michael, additional, McAuley, Danny, additional, Hall, Andrew, additional, Dark, Paul, additional, and McMichael, Andrew, additional

Published
2022
Full Text
View/download PDF

3. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Author

Fisher, Benjamin A, Veenith, Tonny, Slade, Daniel, Gaskell, Charlotte, Rowland, Matthew, Whitehouse, Tony, Scriven, James, Parekh, Dhruv, Balasubramaniam, Madhu S, Cooke, Graham, Morley, Nick, Gabriel, Zoe, Wise, Matthew P, Porter, Joanna, McShane, Helen, Ho, Ling-Pei, Newsome, Philip N, Rowe, Anna, Sharpe, Rowena, Thickett, David R, Bion, Julian, Gates, Simon, Richards, Duncan, Kearns, Pamela, Williams, Bryan, Turner, Rebecca, Libri, Vincenzo, Mussai, Francis, Middleton, Gary, Bowden, Sarah, Bangash, Mansoor, Gao-Smith, Fang, Patel, Jaimin, Sapey, Elizabeth, Thomas, Mark, Coles, Mark, Watkinson, Peter, Rahman, Naj, Angus, Brian, Mentzer, Alexander J., Novak, Alex, Feldman, Marc, Richter, Alex, Faustini, Sian, Bathurst, Camilla, Van de Wiel, Joseph, Mee, Susie, James, Karen, Rahman, Bushra, Turner, Karen, Hill, Adam, Gordon, Anthony, Yap, Christina, Matthay, Michael, McAuley, Danny, Hall, Andrew, Dark, Paul, and McMichael, Andrew

Abstract

Dysregulated inflammation is associated with poor outcomes in COVID-19. We aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating factor inhibitor) and infliximab (a tumour necrosis factor inhibitor) in hospitalised patients with COVID-19, to prioritise agents for phase 3 trials.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results